Payment overview · 2025
General Payments
$130,137.06
303 reported records · 14 companies
Healthcare provider profile · identity verified
Maranda Dillon, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FLOWOOD, MS · NPI 1376072413
Verified facts
What the public records show
CMS Open Payments records show Maranda Dillon, NP-C received $130,137.06 in general payments during 2025 across 303 reported records.
Janssen Biotech, Inc. accounted for 64.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entyvio, Rinvoq, Skyrizi, Stelara, Xeljanz.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SKYRIZI as an associated drug or biological on 322790 records involving 36751 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Skyrizi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REMICADE as an associated drug or biological on 113 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Remicade by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported STELARA as an associated drug or biological on 23706 records involving 7279 distinct recipient NPIs. Public Medicare Part D data also shows 656 claims for Stelara by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REMICADE as an associated drug or biological on 193 records involving 110 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Remicade by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported STELARA as an associated drug or biological on 233 records involving 190 distinct recipient NPIs. Public Medicare Part D data also shows 656 claims for Stelara by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xeljanz by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTYVIO as an associated drug or biological on 61580 records involving 14953 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Entyvio by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $84,191.69 | 64.7% | 135 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17,763.87 | 13.7% | 40 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14,328.92 | 11.0% | 56 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $5,515.15 | 4.2% | 16 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $3,337.82 | 2.6% | 14 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $2,767.85 | 2.1% | 4 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $877.52 | 0.7% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $729.08 | 0.6% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $443.60 | 0.3% | 8 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $71.59 | 0.1% | 3 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $58.58 | 0.1% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.87 | 0.0% | 1 | 2025 |
| Intercept Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.04 | 0.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $10.48 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $78,539.36 | 50 |
| Travel and Lodging | $35,899.28 | 58 |
| Food and Beverage | $7,181.29 | 185 |
| Consulting Fee | $5,769.00 | 5 |
| Honoraria | $2,728.00 | 3 |
| Education | $20.13 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $84,777.84 | 145 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $16,648.03 | 35 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $8,125.48 | 47 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $6,717.89 | 40 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $5,033.38 | 15 | 2025 |
Source payment records
|
|||||
| ZYMFENTRA Normalized: zymfentra |
Biological | Celltrion USA Inc. | $3,242.59 | 7 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $716.33 | 3 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $443.60 | 8 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $95.23 | 7 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $78.94 | 4 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $71.59 | 3 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $58.58 | 3 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.92 | 3 | 2025 |
Source payment records
|
|||||
| OCALIVA Normalized: ocaliva |
Drug | Intercept Pharmaceuticals, Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $11.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTYVIO entyvio |
2025 | Entyvio | 2024 | 102 | exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SKYRIZI skyrizi |
2025 | Skyrizi | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| STELARA stelara |
2025 | Stelara | 2024 | 656 | exact normalized | Medicare Part D |
| XELJANZ xeljanz |
2025 | Xeljanz | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SKYRIZI open payments reported associated product |
CMS Open Payments — General Payments 322790 supporting records · 36751 recipient NPIs · example record 1201352600 |
Skyrizi · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | REMICADE open payments reported associated product |
CMS Open Payments — General Payments 113 supporting records · 89 recipient NPIs · example record 1174377572 |
Remicade · 2024 Exact normalized brand match · 1 Part D row |
125 | 18 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | STELARA open payments reported associated product |
CMS Open Payments — General Payments 23706 supporting records · 7279 recipient NPIs · example record 1174257377 |
Stelara · 2024 Exact normalized brand match · 1 Part D row |
656 | 100 |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | REMICADE open payments reported associated product |
CMS Open Payments — General Payments 193 supporting records · 110 recipient NPIs · example record 1174148007 |
Remicade · 2024 Exact normalized brand match · 1 Part D row |
125 | 18 |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | STELARA open payments reported associated product |
CMS Open Payments — General Payments 233 supporting records · 190 recipient NPIs · example record 1174148007 |
Stelara · 2024 Exact normalized brand match · 1 Part D row |
656 | 100 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | ENTYVIO open payments reported associated product |
CMS Open Payments — General Payments 61580 supporting records · 14953 recipient NPIs · example record 1223616258 |
Entyvio · 2024 Exact normalized brand match · 1 Part D row |
102 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Stelara | Ustekinumab | 656 | 100 |
| Sodium Chloride | 0.9 % Sodium Chloride | 220 | 46 |
| Omeprazole | Omeprazole | 133 | 38 |
| Remicade | Infliximab | 125 | 18 |
| Entyvio | Vedolizumab | 102 | 18 |
| Mesalamine | Mesalamine | 77 | 23 |
| Sulfasalazine | Sulfasalazine | 69 | 21 |
| Mesalamine Er | Mesalamine | 63 | 17 |
| Famotidine | Famotidine | 58 | 25 |
| Humira(Cf) Pen | Adalimumab | 49 | suppressed |
| Rinvoq | Upadacitinib | 44 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 14 |
| Azathioprine | Azathioprine | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 22 |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Skyrizi On-Body | Risankizumab-Rzaa | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Budesonide Dr | Budesonide | 25 | 15 |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 22 | suppressed |
| Prednisone | Prednisone | 20 | 16 |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Skyrizi | Risankizumab-Rzaa | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Avsola | Infliximab-Axxq | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Dextrose In Water | Dextrose 5 % In Water | 12 | suppressed |
| Xeljanz | Tofacitinib Citrate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130,137.06 · 303 records | Janssen Biotech, Inc. | ENTYVIO, EOHILIA, GATTEX, IQIRVO, OCALIVA, OMVOH, REZDIFFRA, RINVOQ, SIMPONI, SIMPONI ARIA, SKYRIZI, STELARA, TREMFYA, VEGZELMA, VELSIPITY, XELJANZ, ZENPEP, ZYMFENTRA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entyvio play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error